Literature DB >> 34962844

Impact of Pharmacist-Driven Transitions of Care Interventions on Post-hospital Outcomes Among Patients With Coronary Artery Disease: A Systematic Review.

Erin Weeda1,2,3, Rachael E Gilbert1,2, Shelby J Kolo1,2, Jason S Haney1,2,3, Linh Tran Hazard3, David J Taber1,2,4, Robert Neal Axon1,2,5.   

Abstract

BACKGROUND: Transitions of care (ToC) aim to provide continuity while preventing loss of information that may result in poor outcomes such as hospital readmission. Readmissions not only burden patients, they also increase costs. Given the high prevalence of coronary artery diseases (CAD) in the United States (US), patients with CAD often make up a significant portion of hospital readmissions.
OBJECTIVE: To conduct a systematic review evaluating the impact of pharmacist-driven ToC interventions on post-hospital outcomes for patients with CAD.
METHODS: MEDLINE, Scopus, and CINAHL were searched from database inception through 03/2020 using key words for CAD and pharmacists. Studies were included if they: (1) identified adults with CAD at US hospitals, (2) evaluated pharmacist-driven ToC interventions, and (3) assessed post-discharge outcomes. Outcomes were summarized qualitatively.
RESULTS: Of the 1612 citations identified, 11 met criteria for inclusion. Pharmacist-driven ToC interventions were multifaceted and frequently included medication reconciliation, medication counseling, post-discharge follow-up and initiatives to improve medication adherence. Hospital readmission and emergency room visits were numerically lower among patients receiving vs not receiving pharmacist-driven interventions, with statistically significant differences observed in 1 study. Secondary prevention measures and adherence tended to be more favorable in the pharmacist-driven intervention groups.
CONCLUSION: Eleven studies of multifaceted, ToC interventions led by pharmacists were identified. Readmissions were numerically lower and secondary prevention measures and adherence were more favorable among patients receiving pharmacist-driven interventions. However, sufficiently powered studies are still required to confirm these benefits.

Entities:  

Keywords:  acute coronary syndrome; cardiology; discharge planning; medication therapy management; myocardial infarction; pharmaceutical care

Year:  2021        PMID: 34962844      PMCID: PMC9427131          DOI: 10.1177/08971900211064155

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  25 in total

1.  Systematic Review and Meta-analysis of Pharmacist-Led Transitions of Care Services on the 30-Day All-Cause Readmission Rate of Patients with Congestive Heart Failure.

Authors:  Connor McKay; Chanhyun Park; Jongwha Chang; Marcia Brackbill; Jae-Young Choi; Jung Heon Lee; Sean Hyungwoo Kim
Journal:  Clin Drug Investig       Date:  2019-08       Impact factor: 2.859

2.  RoB 2: a revised tool for assessing risk of bias in randomised trials.

Authors:  Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins
Journal:  BMJ       Date:  2019-08-28

3.  Impact of Pharmacist Involvement in Heart Failure Transition of Care.

Authors:  Rachel Neu; Melvin A Leonard; Michelle L Dehoorne; Samantha J Scalia; Pramodini B Kale-Pradhan; Christopher A Giuliano
Journal:  Ann Pharmacother       Date:  2019-10-11       Impact factor: 3.154

4.  Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial.

Authors:  Sunil Kripalani; Christianne L Roumie; Anuj K Dalal; Courtney Cawthon; Alexandra Businger; Svetlana K Eden; Ayumi Shintani; Kelly Cunningham Sponsler; L Jeff Harris; Cecelia Theobald; Robert L Huang; Danielle Scheurer; Susan Hunt; Terry A Jacobson; Kimberly J Rask; Viola Vaccarino; Tejal K Gandhi; David W Bates; Mark V Williams; Jeffrey L Schnipper
Journal:  Ann Intern Med       Date:  2012-07-03       Impact factor: 25.391

5.  Impact of an outpatient pharmacist intervention on medication discrepancies and health care resource utilization in posthospitalization care transitions.

Authors:  Emily M Hawes; Whitney D Maxwell; Sarah F White; Jesica Mangun; Feng-Chang Lin
Journal:  J Prim Care Community Health       Date:  2013-09-17

6.  Impact of a Multidisciplinary Heart Failure Post-hospitalization Program on Heart Failure Readmission Rates.

Authors:  Cynthia A Jackevicius; Noelle K de Leon; Lingyun Lu; Donald S Chang; Alberta L Warner; Freny Vaghaiwalla Mody
Journal:  Ann Pharmacother       Date:  2015-08-10       Impact factor: 3.154

7.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

8.  Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial.

Authors:  P Michael Ho; Anne Lambert-Kerzner; Evan P Carey; Ibrahim E Fahdi; Chris L Bryson; S Dee Melnyk; Hayden B Bosworth; Tiffany Radcliff; Ryan Davis; Howard Mun; Jennifer Weaver; Casey Barnett; Anna Barón; Eric J Del Giacco
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

9.  Effect of a care transition intervention by pharmacists: an RCT.

Authors:  Karen B Farris; Barry L Carter; Yinghui Xu; Jeffrey D Dawson; Constance Shelsky; David B Weetman; Peter J Kaboli; Paul A James; Alan J Christensen; John M Brooks
Journal:  BMC Health Serv Res       Date:  2014-09-18       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.